Verona Pharma Plc's ROA from the second quarter of 2025 to the second quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Verona Pharma Plc's ROA in the second quarter of 2025?
Verona Pharma Plc recorded a cumulative net loss of $-81 million during 12 months ending in the second quarter of 2025, resulting in a negative return on assets (ROA) of -15.23%.

However, within the Healthcare sector 338 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2025 quarter, so far to 3491, from total ROA ranking in the first quarter of 2025 at 3958.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter
Y / Y Total Assets Change	32.34 %	81.9 %	56.95 %	30.21 %	42.43 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-81	-164	-173	-154	-125
Return On Assets (TTM)	-15.23 %	-32.92 %	-39.5 %	-40.49 %	-35.08 %
VRNA's Total Ranking	# 3491	# 3958	# 4724	# 4169	# 4091
Total Assets (TTM) in million	573	525	654	381	433
Seq. Total Assets Change	9.2 %	-19.78 %	71.71 %	-12.02 %	50.09 %
Seq. Net Income Change	-	-	-	-	-

VRNA's 5 Years Annual ROA >> Back to VRNA Management Effectiveness >> Compare VRNA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 121
Sector	# 339
Overall	# 3445

Return On Assets Statistics
High	Average	Low
-16.61 %	-29.24 %	-43.9 %
(Jun 30 2025)		(Dec 31 2024)

Financial Statements
Verona Pharma Plc's Assets	$ 573 million	VRNA's Balance sheet
Verona Pharma Plc's Income	$ 12 million	Quarterly VRNA's Income Statement
VRNA's Income by Division		See VRNA's Income by Division

Annual Return On Assets	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020
Y / Y Total Assets Change	56.95 %	21.65 %	54.27 %	-5.98 %	325.5 %
Total Assets in million	654	417	343	222	236
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-173	-54	-69	-56	-65
Annual Return On Assets	-26.52 %	-13.05 %	-20.06 %	-25.03 %	-27.59 %

VRNA's 5 Years Annual ROA >> Back to VRNA Management Effectiveness >> Compare VRNA ROA to its Competitors

More Return On Assets Ratios
VRNA's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
VRNA's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for VRNA's Competitors
Subscribers only: Roa for Verona Pharma Plc's Suppliers
Subscribers only: Return On Assets for VRNA's Customers

You may also want to know
VRNA's Roi	VRNA's Inventory Turnover Ratio	VRNA's Growth Rates	VRNA's Dividend Comparisons
	VRNA's Profitability Ratios	VRNA's Asset Turnover Ratio	VRNA's Dividend Growth
VRNA's Roe	VRNA's Valuation Ratios	VRNA's Financial Strength Ratios	VRNA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2025, within Healthcare Sector

ROA

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.